---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000017"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:47:00.587137+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Entrada reports FY2022 net loss $94.6M; Vertex deal adds $224M upfront, extends cash into 2H 2025

## Summary
- Net loss $24.6M Q4, $94.6M FY2022; R&D expenses $15.7M Q4, $66.6M FY2022.
- Cash, equivalents & securities $188.7M at Dec 31, 2022; runway extended into 2H 2025 after Vertex deal.
- Vertex collaboration closed Feb 2023: $224M upfront + $26M equity; up to $485M milestones plus royalties.
- FDA clinical hold on ENTR-601-44 IND; company working to resolve, aiming for healthy volunteer trial in 2023.
- Selected ENTR-601-45 for Duchenne exon 45 skipping; IND planned for Q4 2024.

## SEC filing metadata
- accession: 0001689375-23-000017
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/0001689375-23-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/trda-20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000017
- JSON: https://secwatch.observer/filing/0001689375-23-000017.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000017.txt

## Key facts
- Earnings Releases
  Entrada Therapeutics, Inc. reported the fourth quarter and full year ending December 31, 2022 results: net income Net loss was $24.6 million for the fourth quarter of 2022 and $94.6 million for the full year of 2022.
  - Period: the fourth quarter and full year ending December 31, 2022
  - Net income: Net loss was $24.6 million for the fourth quarter of 2022 and $94.6 million for the full year of 2022
  - Result: reported results
  source text: Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2022 and other corporate updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000017/0001689375-23-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.